Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The companys marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol Check, a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The companys pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth Check, a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Instruments & Supplies
- Sub-Industry: N/A
- Symbol: NASDAQ:AKER
- CUSIP: N/A
- Web: www.akerslaboratories.com
Capitalization:- Market Cap: $8.1 million
- Outstanding Shares: 8,901,000
Average Prices:- 50 Day Moving Avg: $0.97
- 200 Day Moving Avg: $1.30
- 52 Week Range: $0.85 - $3.60
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 2.68
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.13 million
- Price / Sales: 2.59
- Book Value: $0.57 per share
- Price / Book: 1.60
Profitability:- EBIDTA: ($3,590,000.00)
- Net Margins: -89.49%
- Return on Equity: -59.94%
- Return on Assets: -45.73%
Debt:- Current Ratio: 3.40%
- Quick Ratio: 1.90%
Misc:- Average Volume: 66,566 shs.
- Beta: -0.13
- Short Ratio: 7.55
Frequently Asked Questions for Akers Biosciences (NASDAQ:AKER)
What is Akers Biosciences' stock symbol?
Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."
How were Akers Biosciences' earnings last quarter?
Akers Biosciences Inc (NASDAQ:AKER) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.04. The company earned $1.20 million during the quarter. Akers Biosciences had a negative net margin of 89.49% and a negative return on equity of 59.94%. View Akers Biosciences' Earnings History.
When will Akers Biosciences make its next earnings announcement?
Who are some of Akers Biosciences' key competitors?
Some companies that are related to Akers Biosciences include Transgenomic (PRPO), Nivalis Therapeutics (ALPN), Anthera Pharmaceuticals (ANTH), OpGen (OPGN), Novogen Limited (NVGN), Kitov Pharmaceuticals Holdings (KTOV), Galena Biopharma (GALE), Cytori Therapeutics (CYTX), CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (COTQF), Celsion Corporation (CLSN), Soligenix (SNGX), Lombard Medical (EVAR), Immune Pharmaceuticals (IMNP), RXi Pharmaceuticals Corporation (RXII), DelMar Pharmaceuticals (DMPI), Mateon Therapeutics (MATN), Repros Therapeutics (RPRX) and Argos Therapeutics (ARGS).
Who owns Akers Biosciences stock?
Akers Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Bard Associates Inc. (1.82%). Company insiders that own Akers Biosciences stock include Gary M Rauch, John J Gormally and Raymond Francis Akers Jr. View Institutional Ownership Trends for Akers Biosciences.
How do I buy Akers Biosciences stock?
Shares of Akers Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akers Biosciences' stock price today?
One share of Akers Biosciences stock can currently be purchased for approximately $0.91.
MarketBeat Community Rating for Akers Biosciences (NASDAQ AKER)MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Akers Biosciences (NASDAQ:AKER) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Akers Biosciences (NASDAQ:AKER)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Akers Biosciences (NASDAQ:AKER)Earnings History by Quarter for Akers Biosciences (NASDAQ AKER)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | | | | | | N/A |  |
| 8/14/2017 | 6/30/2017 | ($0.04) | ($0.08) | | $1.20 million | View | N/A | |
| 5/16/2017 | 3/31/2017 | | ($0.19) | | $0.67 million | View | N/A | |
| 11/14/2016 | Q316 | $0.04 | $0.06 | | $0.61 million | View | N/A | |
| 8/11/2016 | Q216 | | ($0.19) | | $0.96 million | View | Listen | |
| 11/13/2015 | Q315 | | ($0.36) | | $0.17 million | View | Listen | |
| 8/18/2015 | Q215 | | ($0.41) | $1.35 million | $0.97 million | View | Listen | |
| 5/14/2015 | Q115 | ($0.10) | ($0.26) | $2.00 million | $0.51 million | View | Listen | |
| 11/13/2014 | Q314 | ($0.17) | ($0.23) | $1.40 million | $453.30 million | View | N/A | |
| 8/12/2014 | Q2 2014 | ($0.16) | ($0.10) | | $1.35 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Akers Biosciences (NASDAQ:AKER)Current Year EPS Consensus Estimate: $-0.25 EPS
Next Year EPS Consensus Estimate: $0.34 EPS
Dividend History for Akers Biosciences (NASDAQ:AKER)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Akers Biosciences (NASDAQ:AKER)
Latest Headlines for Akers Biosciences (NASDAQ:AKER)
| Source: |
|
| Date | Headline |
|---|
 | Akers Biosciences, Inc. :AKER-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017
finance.yahoo.com - September 7 at 3:40 PM |
 | Akers Biosciences Interim Loss Narrows As Allergy Test Sales Grow
www.morningstar.co.uk - August 15 at 4:43 PM |
 | Akers Biosciences Inc (AKER) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM |
| IHS Markit Score Update: Drop in demand for ETFs holding Akers Biosciences Inc is a negative sign for its shares
finance.yahoo.com - August 9 at 8:55 PM |
| Akers Biosciences Second Quarter Revenue Up 25% On Prior Year
www.morningstar.co.uk - August 3 at 4:38 PM |
| Akers Biosciences Inc (NASDAQ:AKER) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:18 AM |
| Akers Biosciences Proposes Executive Chair, CEO Appointment To Board
www.morningstar.co.uk - July 14 at 5:32 PM |
| Akers Biosciences Issues 3,500 Shares Following Warrants Exercise (ALLISS)
www.morningstar.co.uk - June 9 at 3:38 PM |
| Akers Biosciences, Inc. :AKER-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 10:30 AM |
| Akers Biosciences Inc (AKER) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - May 18 at 4:40 PM |
| Akers Biosciences Inc (AKER) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 17 at 10:02 AM |
 | BRIEF-Akers Biosciences reports 10 pct fall in Q1 revenue
www.reuters.com - May 16 at 8:31 PM |
 | Akers Biosciences' (AKER) CEO John Gormally on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 8:31 PM |
| Akers Biosciences Updates on Akers Wellness(TM) Tests
finance.yahoo.com - April 24 at 10:51 AM |
| Akers Biosciences (AKER) Receiving Somewhat Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 18 at 8:51 AM |
| Akers Biosciences, Inc. :AKER-US: Earnings Analysis: Q4, 2016 By the Numbers : April 13, 2017
finance.yahoo.com - April 13 at 3:38 PM |
| Edited Transcript of AKER earnings conference call or presentation 11-Apr-17 1:00pm GMT
finance.yahoo.com - April 12 at 11:45 AM |
| Akers Bioscience 2016 Loss Narrows Amid Sales Growth, Cost Cutting
www.morningstar.co.uk - April 11 at 3:27 PM |
| Akers Biosciences to Commercialize Heparin PF4 Rapid Test in Puerto Rico
finance.yahoo.com - April 10 at 3:25 PM |
| BRIEF-Akers Biosciences files for non-timely 10-K - SEC filing
www.reuters.com - April 1 at 10:04 AM |
| BRIEF-Akers Biosciences reports preliminary unaudited earnings highlights for fiscal year 2016
www.reuters.com - March 31 at 3:32 PM |
| BRIEF-Akers Biosciences announces a $2 million private placement
www.reuters.com - March 30 at 8:50 PM |
| Akers Biosciences Delays Results But Says Revenue Up 40% In 2016
www.morningstar.co.uk - March 30 at 8:50 PM |
| Akers Biosciences Announces a $2 Million Private Placement
finance.yahoo.com - March 30 at 8:50 PM |
| Full Year 2016 Akers Biosciences Inc Earnings Release - Time Not Supplied
us.rd.yahoo.com - March 30 at 3:50 PM |
 | Akers Biosciences Reports Preliminary Unaudited Earnings Highlights for Fiscal Year 2016
us.rd.yahoo.com - March 30 at 3:50 PM |
| Akers Biosciences Announces Conference Call to Discuss FY 2016 Earnings
finance.yahoo.com - March 29 at 10:14 AM |
| Akers Receives Cholesterol Test Kit Order from First Check
finance.yahoo.com - March 29 at 10:14 AM |
| How Will Rapid Cholesterol Test Relate to Potential Future Revenue for Akers
finance.yahoo.com - March 29 at 10:14 AM |
| Diffusion Pharmaceuticals Gets Professional Recognition and Akers Biosciences Achieves a First
finance.yahoo.com - March 29 at 10:14 AM |
 | Mid-Day Market Update: Exeter Gains On Acquisition News; CryoPort Shares Slide
www.nasdaq.com - March 28 at 3:26 PM |
| BRIEF-Akers Biosciences begins selling rapid cholesterol test
www.reuters.com - March 28 at 8:55 AM |
| Akers Gets US Patent For Cartridge Used In BreathScan Lync
www.morningstar.co.uk - February 16 at 7:37 AM |
| Akers Biosciences Allowed US Patent for Akers Wellness(TM) Tests Cartridge
finance.yahoo.com - February 16 at 7:37 AM |
| Akers Biosciences Announces Closing of Public Offering
finance.yahoo.com - January 13 at 8:51 PM |
 | Form 8-K Akers Biosciences Inc For: Jan 13
www.streetinsider.com - January 13 at 3:49 PM |
| AKERS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 13 at 3:49 PM |
| AKERS BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - January 10 at 8:30 PM |
| BRIEF-Akers Biosciences prices 1.6 mln share offering at $1.20 per share
www.reuters.com - January 10 at 3:28 PM |
| 3:20 am Akers Biosciences prices 1,667,000 shares of common stock at $1.20 per share, together with 833,500 five-year warrants to purchase common stock with an exercise price of $1.50
finance.yahoo.com - January 10 at 3:28 PM |
 | Akers Biosciences Announces Pricing of Public Offering of 1,667,000 Shares and 833,500 Warrants
www.marketwatch.com - January 9 at 8:39 PM |
| Form 424B5 Akers Biosciences Inc
www.streetinsider.com - January 6 at 3:32 PM |
| AKERS BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - December 22 at 8:29 PM |
 | Akers Biosciences (AKER) Gains on New York State deal
www.baystreet.ca - December 22 at 3:27 PM |
| Akers Biosciences Signs Rapid Test Deal With US Hospital Association
www.morningstar.co.uk - December 20 at 9:04 AM |
| Akers Biosciences (AKER) Signs Three Agreement with GNYHA to Introduce Heparin PF4 Rapid Test
www.streetinsider.com - December 19 at 3:36 PM |
| Akers Agrees Deal For First Check To Sell Cholesterol Test In US
www.morningstar.co.uk - December 1 at 8:30 PM |
| 5:00 am Akers Biosciences completes the clinical trial for Diabetic Ketoacidosis Breath Test
us.rd.yahoo.com - November 30 at 8:27 PM |
| Akers Biosciences: Clinical Trial For BreathScan "Highly Successful"
www.morningstar.co.uk - November 29 at 1:02 PM |
| Akers Biosciences (AKER) Announces Completion of BreathScan DKA Trial; Results Seen as 'Highly Successful'
www.streetinsider.com - November 29 at 1:02 PM |
Akers Biosciences (AKER) Chart for Friday, September, 22, 2017
